Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.
about
Update on the clinical use of buprenorphine: in opioid-related disordersUtilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependenceA pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disordersThe adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation.A longitudinal study of organizational formation, innovation adoption, and dissemination activities within the National Drug Abuse Treatment Clinical Trials Network.Impact of research network participation on the adoption of buprenorphine for substance abuse treatment.From research to the real world: buprenorphine in the decade of the Clinical Trials NetworkPartnerships and pathways of dissemination: the National Institute on Drug Abuse-Substance Abuse and Mental Health Services Administration Blending Initiative in the Clinical Trials Network.Buprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawalAdoption and implementation of medications in addiction treatment programs.Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation.A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: patterns of sustainability and discontinuationAvailability of nicotine replacement therapy in substance use disorder treatment: longitudinal patterns of adoption, sustainability, and discontinuationBuprenorphine therapy for opioid addiction in rural Washington: the experience of the early adoptersThe prescription of addiction medications after implementation of chronic care management for substance dependence in primary careAdoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programsBarriers to use of pharmacotherapy for addiction disorders and how to overcome them.Influence of religiosity on 12-step participation and treatment response among substance-dependent adolescents.Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages.The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level AnalysisPhysicians in the substance abuse treatment workforce: understanding their employment within publicly funded treatment organizations.Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural CountiesBuprenorphine Prescribing Availability in a Sample of Ohio Specialty Treatment OrganizationsPerceptions of the state policy environment and adoption of medications in the treatment of substance use disorders.Implementing community-based provider participation in research: an empirical study.A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatmentDoes the engagement of clinicians and organisations in research improve healthcare performance: a three-stage reviewAdoption of medications in substance abuse treatment: priorities and strategies of single state authoritiesCounselor training and attitudes toward pharmacotherapies for opioid use disorder.Identifying and ranking implicit leadership strategies to promote evidence-based practice implementation in addiction health servicesTwo Models of Integrating Buprenorphine Treatment and Medical Staff within Formerly "Drug-Free" Outpatient Programs.Treating substance use disorders in the criminal justice system.The relationship between Clinical Trial Network protocol involvement and quality of substance use disorder treatmentI heard about it from a friend: assessing interest in buprenorphine treatment.Narcotics anonymous: a comparison of military veterans and non-veterans.Mise à jour sur l’utilisation clinique de la buprénorphine: pour les troubles reliés aux opioïdes.
P2860
Q26829140-2538D32F-E105-4F21-BF02-75F680464CD1Q26865674-99FB2BDA-1A33-4E37-8DE2-DDACF30C7E72Q27000732-EB579FD3-A902-45B3-BD7D-10311B90F29FQ33716545-5D682C0D-5B9C-4089-BB7A-E9871FFE42E0Q33750845-08BDCD33-F4F0-4B84-B2CF-09DB70AAF7CAQ33776944-51242379-81CC-49A6-9549-25EC22FDC344Q33783274-D5650B73-47A8-4A87-A740-4BE96DE9DC87Q33793165-57FFE74F-95BB-4D75-BED4-2471120C264FQ34552092-D5634E93-EAEF-4951-86D8-3F2C8E6A3F0EQ34607338-DDD3D116-B8F7-455A-B101-11CBFB72348DQ34925449-08347233-018C-464B-AD16-8AF57A8F238AQ35075932-E6FCD52A-F635-499C-9987-028664F58CBEQ35147373-BC401DDA-A67B-4B4D-986B-880936294679Q35199231-FEA94148-9709-41B1-AEB8-10BCD27C2A79Q35243514-5FBFAD02-6308-4779-A13F-279B0BA1088EQ35447234-E02DBFA2-0CE9-4D26-A9A5-6B3B99A401ECQ35490468-EC817337-CEA0-4C9D-8962-2ABC652B3741Q35538130-A5B7E6F5-9E8F-4C06-92DB-2C957DCFEFD8Q35577449-4AFCDA18-D099-4C85-8BB2-EFF18AC6B504Q35828982-8672F2CD-62D6-4ECB-81BC-C75603ADAFAFQ35937004-B59233EF-83D6-4663-A265-982DE1888CDDQ36054084-8F5FAC2C-9316-4C05-B4DC-372DD4F386E2Q36058075-CD5971C3-018E-4ED1-8022-1C4EAF36A872Q36192673-DA420B46-F009-4927-8059-C9C8108C7252Q36351763-470AF918-A1E7-422C-9AD5-BF314EFE994FQ36364490-371C884F-39D2-4D4D-A36E-DF171463E21BQ36374374-9136F93E-4FBB-4312-9CAC-9513748546AEQ36806539-E1F9283A-F234-454E-9279-5C1213A77853Q36934945-08176F7D-5B46-40FE-9CF5-23C4BFF37166Q36972481-510F57C1-D49A-46C1-BE66-F0E6641FA3B6Q37115985-903DABF1-6D99-403B-B6B7-ADF7A22A0372Q37383188-1A82C10A-DA0A-4408-85B3-CF9C21BDDD90Q37419480-00026781-4FD3-49D6-BE22-D086F093B82DQ37617894-C9993263-AF27-4002-B770-03C1A9964221Q45328725-6E9EBC92-C995-4075-BB82-F7F343C00465Q45847009-83703430-4B0B-4C49-AE73-9A28D4B4E7AE
P2860
Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.
@en
Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.
@nl
type
label
Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.
@en
Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.
@nl
prefLabel
Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.
@en
Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.
@nl
P2093
P2860
P1476
Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network
@en
P2093
Amanda J Abraham
Hannah K Knudsen
Paul M Roman
P2860
P304
P356
10.1016/J.JSAT.2008.12.004
P577
2009-07-03T00:00:00Z